Shares in Genmab A/S dropped sharply Tuesday on news that its anti-CD20 antibody ofatumumab failed to demonstrate a significant objective response rate in non-Hodgkins lymphoma (NHL) patients who were refractory to other treatments. (BioWorld Today) Read More
